1.Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
Wootaek SEO, ; Hyeon-Gi KIM ; Hee-Eon LIM ; Kwangrok JUNG ; Jong-Chan LEE ; Jin-Hyeok HWANG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2025;30(2):76-80
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
2.Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
Wootaek SEO, ; Hyeon-Gi KIM ; Hee-Eon LIM ; Kwangrok JUNG ; Jong-Chan LEE ; Jin-Hyeok HWANG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2025;30(2):76-80
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
3.Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
Wootaek SEO, ; Hyeon-Gi KIM ; Hee-Eon LIM ; Kwangrok JUNG ; Jong-Chan LEE ; Jin-Hyeok HWANG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2025;30(2):76-80
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
4.Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
Wootaek SEO, ; Hyeon-Gi KIM ; Hee-Eon LIM ; Kwangrok JUNG ; Jong-Chan LEE ; Jin-Hyeok HWANG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2025;30(2):76-80
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
5.Small Cell Transformation in Pancreatic Metastasis from EGFR-Mutated Lung Adenocarcinoma Following TKI
Wootaek SEO, ; Hyeon-Gi KIM ; Hee-Eon LIM ; Kwangrok JUNG ; Jong-Chan LEE ; Jin-Hyeok HWANG ; Jaihwan KIM
Korean Journal of Pancreas and Biliary Tract 2025;30(2):76-80
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). This case report presents a rare instance of small cell carcinoma transformation in pancreatic metastasis in a patient with EGFR-mutated NSCLC undergoing treatment with lazertinib. Small cell carcinoma transformation indicates a mechanism of treatment resistance, and tissue biopsy is essential to confirm this. When isolated progression of a lesion is suspected during TKI therapy in EGFR-mutated NSCLC, histological evaluation is necessary to confirm the transformation for the treatment strategy.
6.Caregiver Burden of Patients With Huntington’s Disease in South Korea
Chan Young LEE ; Chaewon SHIN ; Yun Su HWANG ; Eungseok OH ; Manho KIM ; Hyun Sook KIM ; Sun Ju CHUNG ; Young Hee SUNG ; Won Tae YOON ; Jin Whan CHO ; Jae-Hyeok LEE ; Han-Joon KIM ; Hee Jin CHANG ; Beomseok JEON ; Kyung Ah WOO ; Seong-Beom KOH ; Kyum-Yil KWON ; Jangsup MOON ; Young Eun KIM ; Jee-Young LEE
Journal of Movement Disorders 2024;17(1):30-37
Objective:
This is the first prospective cohort study of Huntington’s disease (HD) in Korea. This study aimed to investigate the caregiver burden in relation to the characteristics of patients and caregivers.
Methods:
From August 2020 to February 2022, we enrolled patients with HD from 13 university hospitals in Korea. We used the 12-item Zarit Burden Interview (ZBI-12) to evaluate the caregiver burden. We evaluated the clinical associations of the ZBI-12 scores by linear regression analysis and investigated the differences between the low- and high-burden groups.
Results:
Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study. The average age at onset of motor symptoms was 49.3 ± 12.3 years, with an average cytosine-adenine-guanine (CAG)n of 42.9 ± 4.0 (38–65). The median ZBI-12 score among our caregivers was 17.6 ± 14.2. A higher caregiver burden was associated with a more severe Shoulson–Fahn stage (p = 0.038) of the patients. A higher ZBI-12 score was also associated with lower independence scale (B = -0.154, p = 0.006) and functional capacity (B = -1.082, p = 0.002) scores of patients. The caregiving duration was longer in the high- than in the low-burden group. Caregivers’ demographics, blood relation, and marital and social status did not affect the burden significantly.
Conclusion
HD patients’ neurological status exerts an enormous impact on the caregiver burden regardless of the demographic or social status of the caregiver. This study emphasizes the need to establish an optimal support system for families dealing with HD in Korea. A future longitudinal analysis could help us understand how disease progression aggravates the caregiver burden throughout the entire disease course.
7.Evaluating the Validity and Reliability of the Korean Version of the Scales for Outcomes in Parkinson’s Disease–Cognition
Jinse PARK ; Eungseok OH ; Seong-Beom KOH ; In-Uk SONG ; Tae-Beom AHN ; Sang Jin KIM ; Sang-Myung CHEON ; Yoon-Joong KIM ; Jin Whan CHO ; Hyeo-Il MA ; Mee Young PARK ; Jong Sam BAIK ; Phil Hyu LEE ; Sun Ju CHUNG ; Jong-Min KIM ; Han-Joon KIM ; Young-Hee SUNG ; Do Young KWON ; Jae-Hyeok LEE ; Jee-Young LEE ; Ji Seon KIM ; Ji Young YUN ; Hee Jin KIM ; Jin Yong HONG ; Mi-Jung KIM ; Jinyoung YOUN ; Hui-Jun YANG ; Won Tae YOON ; Sooyeoun YOU ; Kyum-Yil KWON ; Su-Yun LEE ; Younsoo KIM ; Hee-Tae KIM ; Joong-Seok KIM ; Ji-Young KIM
Journal of Movement Disorders 2024;17(3):328-332
Objective:
The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to assess cognition in patients with Parkinson’s disease (PD). In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPACog (K-SCOPA-Cog).
Methods:
We enrolled 129 PD patients with movement disorders from 31 clinics in South Korea. The original version of the SCOPA-Cog was translated into Korean using the translation-retranslation method. The test–retest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. Spearman’s rank correlation analysis with the Montreal Cognitive Assessment-Korean version (MOCA-K) and the Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity.
Results:
The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis revealed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively).
Conclusion
Our results demonstrate that the K-SCOPA-Cog has good reliability and validity.
8.Effects of wax rim in image registration of intraoral and face scan in edentulous arch condition
Sang-Hyeok SEO ; Cheong-Hee LEE ; Kyu-Bok LEE ; So-Yeun KIM ; Du-Hyeong LEE
Journal of Dental Rehabilitation and Applied Science 2024;40(3):135-141
Purpose:
The purpose of this study was to investigate the accuracy of image merging of an intraoral scan of an edentulous arch to a facial scan using wax rim and markers. .
Materials and Methods:
For registration of oral scan to face scan, a wax rim with markers wasmade. The markers were cuboid and divided into four groups according to size (5, 10 mm) and attachment location (midline, canine region). The evaluation of registration accuracy was compared with a standard created using cone-beam computed tomographydata. Anterior linear variation of the edentulous arch and the 3D variation of the overall arch were measured. Kruskal-Wallis test and Mann-Whitney U test were used for statistics, and the significance level was set at 0.05 and evaluated under Bonferroni correction (0.05/6 = 0.083).
Results:
In the anterior deviation and global deviation results, there was no statistically significant difference in the oral scan position displacement values between the 5 mm and 10 mm groups. When the midline marker was used, the intraoral scan position displacement value was significantly lower than when only the canine marker was used.
Conclusion
Marker attached wax rim can be used for image matching between facial and intraoral scans of the edentulous arch. Marker location at the middle area increases the accuracy of image matching.
9.Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial
Jun Hee LEE ; Hyeok Jun GOH ; Kisoo LEE ; Dong Won CHOI ; Kwang Min LEE ; Soodong KIM
Investigative and Clinical Urology 2024;65(5):466-472
Purpose:
This study aims to prospectively analyze the effects of anticholinergic therapy using imidafenacin on detrusor overactivity occurring after robot-assisted radical prostatectomy (RARP).
Materials and Methods:
Patients were followed-up at outpatient visits 2–4 weeks post-surgery (visit 2) to confirm the presence of urinary incontinence. Those confirmed with urinary incontinence were randomly assigned in a 1:1 ratio to the anticholinergic medication group (imidafenacin 0.1 mg twice daily) or the control group. Patients were followed-up at 1, 3, and 6 months post-surgery for observational assessments, including the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS).
Results:
A total of 49 patients (25 in the treatment group and 24 in the control group) were randomized for the study. There were no differences observed between the groups in terms of age, comorbidities, prostate size, or pathological staging. According to the IPSS questionnaire results, there was no statistically significant difference between the medication and control groups (p=0.161).However, when comparing storage and voiding symptoms separately, there was a statistically significant improvement in storage symptom scores (p=0.012). OABSS also revealed statistically significant improvement in symptoms from 3 months post-surgery (p=0.005), which persisted until 6 months post-surgery (IPSS storage: p=0.023, OABSS: p=0.013).
Conclusions
In the case of urinary incontinence that occurs after RARP, even if the function of the intrinsic sphincter is sufficiently preserved, if urinary incontinence persists due to changes in the bladder, pharmacological therapy using imidafenacin can be beneficial in managing urinary incontinence.
10.Effects of wax rim in image registration of intraoral and face scan in edentulous arch condition
Sang-Hyeok SEO ; Cheong-Hee LEE ; Kyu-Bok LEE ; So-Yeun KIM ; Du-Hyeong LEE
Journal of Dental Rehabilitation and Applied Science 2024;40(3):135-141
Purpose:
The purpose of this study was to investigate the accuracy of image merging of an intraoral scan of an edentulous arch to a facial scan using wax rim and markers. .
Materials and Methods:
For registration of oral scan to face scan, a wax rim with markers wasmade. The markers were cuboid and divided into four groups according to size (5, 10 mm) and attachment location (midline, canine region). The evaluation of registration accuracy was compared with a standard created using cone-beam computed tomographydata. Anterior linear variation of the edentulous arch and the 3D variation of the overall arch were measured. Kruskal-Wallis test and Mann-Whitney U test were used for statistics, and the significance level was set at 0.05 and evaluated under Bonferroni correction (0.05/6 = 0.083).
Results:
In the anterior deviation and global deviation results, there was no statistically significant difference in the oral scan position displacement values between the 5 mm and 10 mm groups. When the midline marker was used, the intraoral scan position displacement value was significantly lower than when only the canine marker was used.
Conclusion
Marker attached wax rim can be used for image matching between facial and intraoral scans of the edentulous arch. Marker location at the middle area increases the accuracy of image matching.

Result Analysis
Print
Save
E-mail